Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.53 |
| ▸ | GRM5 | P41594 | 11/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25119907 | 0.86 | GRM1 (0.54) | GRM1GRM5PDK4PDE10ATNK2 | |
| SCHEMBL31180111 | 0.83 | PDK4 (0.53) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL31180211 | 0.83 | PDK4 (0.53) | GRM1GRM5PDK4PDE10ANAMPT | |
| SCHEMBL15941818 | 0.81 | GRM5 (0.59) | GRM1GRM5PDK4PDE10ATNK2 | |
| SCHEMBL15942450 | 0.80 | GRM1 (0.50) | GRM1GRM5PDK4PDE10ATNK2 | |
| SCHEMBL1585582 | 0.79 | TNK2 (0.55) | GRM1GRM5PDK4PDE10ATNK2 | |
| SCHEMBL5337565 | 0.79 | GRM1 (0.58) | GRM1GRM5PDK4PDE10ATNK2 | |
| SCHEMBL19297155 | 0.78 | PDK4 (0.60) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL15933052 | 0.77 | GRM1 (0.55) | GRM1GRM5PDK4NAMPTJAK1 | |
| SCHEMBL23703478 | 0.77 | GRM1 (0.57) | GRM1GRM5PDK4NAMPTJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952510-B1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2018-12-26 | — | — | EP | disclosed |
| US-9708295-B2 | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-07-18 | — | — | US | disclosed |
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| EP-2952510-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd (CN) | 2015-12-09 | — | — | EP | disclosed |
| CN-104968654-A | Substituted 2-aminopyridine protein kinase inhibitor | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD | 2015-10-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002205-A1 | SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR | PACSIN2, MAPKAPK2, PRKCA | GRM1 1569/4885GRM5 1470/4885PDK4 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.